.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC16_Guselkumab.Guselkumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC16_Guselkumab.Guselkumab| name: | Guselkumab |
| ATC code: | L04AC16 | route: | subcutaneous |
| n-compartments | 2 |
Guselkumab is a human monoclonal antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23), inhibiting its interaction with the IL-23 receptor. It is approved for the treatment of moderate-to-severe plaque psoriasis in adults and for psoriatic arthritis.
Pharmacokinetics in adult patients with moderate-to-severe plaque psoriasis following subcutaneous administration. Population PK model from pooled clinical trials (brodalumab comparator group) with typical adult subject (mean body weight 90 kg).
Chen, Y, et al., & Sharma, A (2022). Population pharmacokinetics and exposure-response modeling analyses of guselkumab in patients with psoriatic arthritis. Clinical and translational science 15(3) 749–760. DOI:10.1111/cts.13197 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34854241